CSACI position statement: safety of topical calcineurin inhibitors in the ... 7thSpace Interactive (press release) Utilizing topical calcineurin inhibitors (TCIs) for the treatment of AD not responsive to high-potency corticosteroids, or low-potency corticosteroids and localized to the face, eyelids, and skin folds of patients >2 years, is reasonable to include in ... |
